Amgen Inc. (amgn)
AMGN Valuation
| P/E (trailing) | 25.32 |
| P/E (forward) | 16.86 |
| EV/EBITDA | 14.93 |
| Price/Sales | 5.74 |
| Price/Book | 18.73 |
| Market cap | $218.50B |
Amgen Inc. FAQ
What does Amgen Inc. (AMGN) do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque p…
What is AMGN's P/E ratio?
Amgen Inc. has a trailing P/E of 25.32× based on publicly available market data.
Does AMGN pay a dividend?
Indicated dividend yield: 2.5%. Confirm ex-dates and payout history in Vest Terminal.
What sector is AMGN in?
Amgen Inc. is classified in Healthcare (Drug Manufacturers - General) on NMS.
What is AMGN's market capitalization?
Approximate market cap: $218.50B.
What are the main risks for AMGN?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of AMGN?
Potential positives include revenue growth of 9.5% year-over-year, earnings growth of 64.9% year-over-year.
Where can I get analyst estimates for AMGN?
Consensus estimates, price targets, and detailed analyst data for Amgen Inc. are available to Professional subscribers in Vest Terminal — not on this public summary page.